Phaseline

Companies › BioRay Pharmaceutical

BioRay Pharmaceutical: clinical trials, targets and expected readouts

4 active drug programs in 4 registered trials: 2 Phase 1, 1 Phase 2, 1 Phase 3; Oncology, Genitourinary; next expected readout Mar 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Trastuzumab (HS627)
Receptor protein-tyrosine kinase erbB-2 inhibitor
ERBB2Phase 3Breast Cancer–
Rituximab
B-lymphocyte antigen CD20 binding agent
MS4A1Phase 2Primary Membranous NephropathyMar 2027
BR111-101 for injection–Phase 1Advanced MalignanciesOct 2027
BRY812 for injection–Phase 1Advanced MalignanciesAug 2028

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT04514419Trastuzumab (HS627)Phase 3Breast CancerOncologySep 2024
NCT06642909RituximabPhase 2Primary Membranous NephropathyGenitourinaryMar 2027
NCT06937957BR111-101 for injectionPhase 1Advanced MalignanciesOncologyOct 2027
NCT06038058BRY812 for injectionPhase 1Advanced MalignanciesOncologyAug 2028

Targets

MS4A1 (1) ERBB2 (1)

Companies with the same targets

Roche Beijing Biotech Biocad Shanghai Henlius Biotech Jiangsu HengRui Medicine Shenyang Sunshine Pharmaceutical AstraZeneca Acerta Pharma Shanghai JMT-Bio R-Pharm

Companies built like this

SystImmune DualityBio Aston Sci. Chengdu SciMount Pharmatech CSPC Megalith Biopharmaceutical

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.